ABSTRACT Background: Serious infectious morbidity is high in preterm infants. Enteral supplementation of prebiotics may reduce the incidence of serious infections, especially infections related to the gastrointestinal tract. Objective: The objective was to determine the effect of enteral supplementation of a prebiotic mixture consisting of neutral oligosaccharides ( SC GOS/ LC FOS) and acidic oligosaccharides (AOS) on serious infectious morbidity in preterm infants. Design: In a randomized controlled trial, preterm infants (gestational age ,32 wk and/or birth weight ,1500 g) received enteral supplementation of 80% SC GOS/ LC FOS and 20% AOS (1.5 g Á kg
INTRODUCTION
Preterm infants admitted to the neonatal intensive care unit (NICU) have a high risk of serious infections. Although serious infections are often due to bloodstream infections caused by coagulase-negative staphylococci (CoNS), many infections are also caused by endogenous bacteria, which often originate from the gastrointestinal tract (1) . In a recent review of the literature, we found that the number of bifidobacteria and Lactobacillus is lower in the gastrointestinal tract of preterm infants than in term infants, whereas the number of potentially pathogenic bacteria is higher. Furthermore, antibiotic administration after birth causes a significant delay in the intestinal bacterial colonization (2) . Intestinal microbiota have the potential to influence the maturation of the infant's immune system (3, 4) .
Breast-milk oligosaccharides have immunomodulatory, antiadhesive, and antimicrobial effects (5) . The antiadhesive and antimicrobial effect is due to a direct effect of acidic human milk oligosaccharides, which act as receptor analogs to the ligands of pathogens preventing adhesion of pathogens to the epithelial surface (6) . The immunomodulatory effect is thought to be related to the bifidogenic effect of breast milk on the microbiota of the infant's gut (5) . This bifidogenic effect of breast milk is attributable to the large amount of oligosaccharides in breast milk. Nonhuman milk oligosaccharides, such as small-chain galactooligosaccharides ( SC GOS) and long-chain fructooligosaccharides ( LC FOS), are used to substitute these functions (7) . In previous studies in preterm and term infants, supplementation with neutral oligosaccharides stimulated a bifidogenic intestinal flora with a decrease of pathogens (3) (4) (5) . In addition, neutral oligosaccharides increased small-chain fatty acids (SCFAs) production and decreased pH in human studies (6) . In an in vitro model, SCFAs stimulated the mucin-2 synthesis and improved intestinal integrity (8) . Furthermore, SCFAs may decrease the growth of pathogens and has a regulatory role in intestinal motility (6) .
In term infants, supplementation of neutral oligosaccharides to infant formula reduced the incidence of infections and atopy (9) (10) (11) (12) (13) . Of the oligosaccharides in breast milk, '80% are neutral and up to 20% are acidic. Nonhuman milk acidic oligosaccharides (AOS) can be derived from pectin. AOS are able to act as receptors-analogs and are known to inhibit the adhesion of pathogens on the epithelial surface (6) . AOS may also directly effect the immune cells via interaction of selectins, dendritic cell specific C-type lectin, integrins, and other target receptors as Toll-like receptors (6) . The combination of SC GOS/ LC FOS with AOS may increase the growth of a bifidogenic flora, decrease the growth of pathogens in the intestine, have a positive effect on the mucus layer of the gastrointestinal tact, and may stimulate the maturation of the immune system (14-16). As a result of these effects, we hypothesize that preterm infants receiving a combination of SC GOS/ LC FOS with AOS may have a reduced incidence of serious infections. The primary aim of this randomized, double-blind, placebo-controlled trial was to determine the effect of enteral supplementation of a prebiotic mixture consisting of neutral ( SC GOS/ LC FOS) and acidic (AOS) oligosaccharides on serious infectious morbidity in preterm infants. In addition, we determined the effect on feeding tolerance and short-term outcome in preterm infants.
SUBJECTS AND METHODS

Subjects
Infants with a gestational age (GA) ,32 wk and/or birth weight ,1500 g, admitted to the level III NICU of the VU University Medical Center, Amsterdam, were eligible for participation in the study. Exclusion criteria were as follows: infants with a gestational age .34 wk, major congenital or chromosomal anomalies, death within 48 h after birth, and transfer to another hospital within 48 h after birth. The medical ethical review board of our hospital approved the study protocol. Written informed consent was obtained from all parents.
Randomization, blinding, and treatment
After assignment to 1 of 3 birth weight groups ( 799, 800-1199, and !1200 g), the infants were randomly allocated to treatment within 48 h after birth to receive either enteral 80% SC GOS/ LC FOS and 20% AOS or placebo powder (maltodextrin). An independent researcher used a computer-generated randomization table (provided by Danone Research, Friedrichsdorf, Germany) to assign infants to treatment with SC GOS/ LC FOS/ AOS or placebo. Investigators, parents, medical and nursing staff were unaware of treatment allocation. The randomization code was broken after data analysis was performed. SC GOS/ LC FOS/ AOS and the placebo powder (maltodextrin) were prepared and packed sterile (Danone Research, Friedrichsdorf, Germany). The 2 powders were indistinguishable by appearance, color, and smell. During the study period, SC GOS/ LC FOS/AOS and placebo powder were monitored for stability and microbiological contamination.
Supplementation with SC GOS/ LC FOS/AOS or placebo was administered in increasing doses between days 3 and 30 of life to a maximum of 1.5 g Á kg 21 Á d 21 to breast milk or preterm formula. Two members of the nursing staff added the daily supplementation to breast milk or to preterm formula (Nenatal Start; Danone Research, Friedrichsdorf, Germany) according to the parents' choice. Per 100 mL, the preterm formula provided 80 kcal, 2.4 g protein (casein-whey protein ratio 40:60), 4.4 g fat, and 7.8 g carbohydrate. The preterm formula did not contain oligosaccharides. When infants were transferred to another hospital before the end of the study, the protocol was continued under supervision of the principal investigator (EAMW).
Nutritional support
Protocol guidelines for the introduction of parenteral and enteral nutrition followed current practices at our NICU. Nutritional support was administered as previously described (17), except for minimal enteral feeding (defined as 12-24 mL Á kg 21 Á d 21 ), which was advanced from either day 2 or from day 4 in those with a birth weight ,10th percentile, GA ,26 wk, Apgar score ,6 at 5 min, umbilical artery pH ,7.10, or base deficit .10 mmol/L. For each infant in the study, a feeding schedule was proposed based on birth weight and the guidelines as mentioned above. However, the medical staff of our NICU had final responsibility for the administration of parenteral nutrition and advancement of enteral nutrition.
After discharge, all infants received breast milk or preterm formula (Nenatal Start without oligosaccharides) and a postdischarge formula (Nenatal 1 without oligosaccharides) until the corrected age of 6 mo.
Study outcomes
The primary outcome of the study was the effect of SC GOS/ LC FOS/AOS supplementation to the enteral nutrition on serious infectious morbidity (1, 17) during admission in the NICU and during the 80-d follow-up. A new serious infectious episode was defined as a new positive culture after adequate antibiotic treatment of the previous infectious episode with clinical recovery. More than one positive culture with the same bacteria from different sites at the same time was registered as one serious infectious episode. In addition, an analysis was performed of serious infectious morbidity caused by CoNS, most commonly related to (the combination of) indwelling lines and parenteral nutrition and by non-CoNS (=endogenous) infections, usually from microorganisms from the gastrointestinal tract. The occurrence of serious infections was independently determined by 2 investigators (EAMW and RMvE), who were unaware of treatment allocation. Secondary outcomes (during admission and the 80-d follow-up) were feeding tolerance, such as time to full enteral feeding, defined as a feeding volume .120 mL Á kg 21 Á d
21
, age when parenteral feeding was discontinued, days of minimal enteral feeding, defined as 12-
, days of no enteral feeding, and the occurrence of Bell stage II and III necrotizing enterocolitis (18) and growth (19) . Other secondary outcomes were need for mechanical ventilation, presence of periventricular-intraventricular hemorrhage (20) , patent ductus arteriosus treated with ibuprofen, indomethacin and/or surgical ligation, bronchopulmonary dysplasia (BPD) (21) , retinopathy of prematurity (22) , age at discharge from NICU, age at discharge from the hospital, and death.
Statistical analysis
On the basis of the differences in incidences of infectious morbidity (76% and 50%, respectively) in a previous study (17) , a 2-tailed a = 0.05, a b = 0.20, and a sample size of 2 · [2 · 7.85 · 0.63 (0.37)]/(0.26) 2 = 2 · 54 infants were calculated. Normally distributed and nonparametric data were presented as means 6 SDs and median (range), respectively. Logistic regression analysis was performed to determine whether enteral supplementation of SC GOS/ LC FOS/AOS influenced the incidence of serious infections and more than one infectious episode. Multinominal logistic regression analysis was performed to determine whether enteral SC GOS/ LC FOS/AOS supplementation influenced the incidence of serious endogenous infections. In a second analysis, adjustments were made for possible confounding factors: gestational age, birth weight, Apgar score ,6 at 5 min, and exclusive breastfeeding during the study period (defined as the first 30 d of life.) Secondary outcomes were analyzed by Student's t test, Mann-Whitney U test, and chi-square test or Fisher's exact test for continuous normally distributed, nonparametric continuous, and dichotomous data, respectively.
All statistical analyses were performed on an intention-to-treat basis. To determine the effect of sufficient dosage and time of exposure to supplementation, a per-protocol analysis was performed, excluding infants who received a mean supplementation dose ,50% of the maximum supplementation dose (1.5 g Á kg 21 Á d 21 ) during the study period and infants not completing the study period (30 d of life). For all statistical analyses, a 2-tailed P value ,0.05 was considered significant. SPSS 15.0 (SPSS Inc, Chicago, IL) was used for the data analysis.
RESULTS
Between May 2007 and November 2008, 113 preterm infants entered the study. The trial profile is shown in Figure 1 . Baseline patient and nutritional characteristics were not different between the 2 groups ( Table 1 ). In the SC GOS/ LC FOS/AOSsupplemented group, 23 of 55 (42%) infants had !1 serious Table 2) . In an additional analysis, adjustment for gestational age, birth weight, Apgar score ,6 at 5 min, and exclusive breastfeeding during the 30-d study period did not change the results of the crude analysis ( Table 2) .
The relation of the first endogenous infection with postnatal age is shown in a Kaplan-Meier curve ( Figure 2) . The first serious infection occurred at a median postnatal age of 8 d in both groups. The first endogenous infection occurred at a median postnatal age of 16 d in both groups. In both groups, the most frequently cultured endogenous microorganism was Staphylococcus aureus ( Table 3) .
None of the secondary outcomes were significantly different between the SC GOS/ LC FOS/AOS-supplemented group and the placebo group, except for mild BPD: 1 of 52 (2%) and 10 of 52 (19%), respectively (OR: 0.08; 95% CI: 0.01, 0.67; P = 0.004; Table 4 ).
Infants excluded from the per-protocol analysis received a mean supplementation dose during the 30-d study period of 0.48 6 0.31 g Á kg 21 Á d
21
.
In the per-protocol analysis (n = 94), 26 of 43 (61%) subjects in the SC GOS/ LC FOS/AOS-supplemented group and 30 of 51 (59%) subjects in the placebo group were exclusively breastfed during the 30-d study period. There was a trend toward a lower incidence of !1 serious infection in the SC GOS/ LC FOS/AOS-supplemented group (13 of 43; 30%) than in the placebo group (25 of 51; 49%) (OR: 0.45; 95% CI: 0.19, 1.10; P = 0.06). The incidence of !1 serious endogenous infection was lower in the SC GOS/ LC FOS/AOS-supplemented group (5 of 43; 12%) than in the placebo group (14 of 51; 28%) (OR: 0.31; 95% CI: 0.10, 0.98; P = 0.045). The incidence of !2 serious infections episodes was lower in the SC GOS/ LC FOS/ AOS-supplemented group (2 of 43; 5%) than in the placebo group (10 of 51; 20%) (OR: 0.20; 95% CI: 0.04, 0.97; P = 0.03) ( Table 2) . In an additional analysis, adjustment for gestational age, birth weight, Apgar score ,6 at 5 min, and exclusive breastfeeding during the 30-d study period decreased the OR and increased the P value to .0.05 for endogenous infections (OR: 0.29; 95% CI: 0.07, 1.22; P = 0.09) and !2 infectious episodes (OR: 0.16; 95% CI: 0.02, 1.20; P = 0.07) ( Table 2 ). The incidence of mild BPD (21) was lower in the SC GOS/ LC FOS/ AOS-supplemented group (0 of 43; 0%) than in the placebo group (9 of 39; 23%) (P = 0.003).
DISCUSSION
To our knowledge, this was the first study to describe the effects of enteral supplementation of a prebiotic mixture of SC GOS/ LC FOS and AOS on serious infectious morbidity and short-term outcomes in preterm infants. Although there was a clear trend, enteral supplementation with SC GOS/ LC FOS/AOS did not significantly reduce the risk of serious infections in preterm infants. Interestingly we observed that, as one of the secondary outcomes, the incidence of mild BPD was lower in the enteral SC GOS/ LC FOS/AOS-supplemented group.
Preterm infants face many challenges, and performing an intervention study in this high-risk group is a challenge. Because of their increased risk of infectious morbidity with paralytic ileus and necrotizing enterocolitis, increasing enteral feeding is often difficult. Prebiotics increase the intestinal growth of Bifidobacteria and Lactobacillus and reduce the amount of potentially pathogenic bacteria (23). However, because of feeding problems and excessive antibiotic use in very-low-birth weight preterm infants, sufficient amounts of study supplements could not always be administered to accomplish a beneficial effect on the intestinal flora. Besides an improved balance between healthpromoting bacteria and potentially pathogenic bacteria, other factors, such as improved intestinal integrity reflected by intestinal permeability, improved intestinal motility, the interaction between the intestinal microbiota, and the gut and inhibition of adhesion of pathogens to the epithelial surface may be involved in the susceptibility to endogenous infections in preterm infants.
The incidence of endogenous infections and !2 serious infections episodes was lower in infants who received a mean supplementation dose of !50% of the maximum supplementation dose of 1.5 g Á kg 21 Á d 21 during the study period (per-protocol 1 Serious infectious morbidity was defined as sepsis, meningitis, pyelonephritis, or pneumonia diagnosed by a combination of clinical signs and a culture positive for microorganisms. OR, odds ratio.
2 Adjusted for gestational age, birth weight, Apgar score ,6 at 5 min, and exclusive breastfeeding during the 30-d study period.
3 Logistic regression analysis. 4 Multinominal logistic regression analysis.
analysis).This is in line with the results of the study by Moro et al (24) , who showed a dose dependent effect of SC GOS/ LC FOS (0.8 g/dL compared with 0.4 g/dL during a 28-d study period) on the growth of Bifidobacteria and Lactobacillus in the intestine. In our study, the median time to full supplementation was 11 d, the time to the first serious endogenous infection was 16 d, and the time to the second serious infectious episode was 27 d. This suggests that enteral supplementation of SC GOS/ LC FOS/AOS of preterm infants may reduce the risk of serious infectious morbidity, especially endogenous infections, if supplementation is given at a dose of !50% of the maximum of 1.5 g Á kg 21 Á d 21 and is given for !14 d. This effect is in line with the ability of AOS to act as receptors-analogs, resulting in inhibition of the adhesion of pathogens on the epithelial surface in the gastrointestinal tract (6). However, our study was not designed to determine the optimal supplementation dose and number of days required to reduce serious infections.
We observed that the incidence of mild BPD, as defined by Jobe et al (21) , was lower in the enteral SC GOS/ LC FOS/AOSsupplemented group than in the placebo group, also after adjustment for chorioamnionitis, gestational age, birth weight, and serious infectious morbidity. Although the development of BPD is multifactorial, inflammation is considered an important factor associated with BPD (25) (26) (27) . We hypothesize that enteral supplementation with SC GOS/ LC FOS/AOS may influence the immune system and the systemic inflammatory response in the respiratory tract, improving the balance between proinflammatory and inflammatory cytokines. Previous studies have shown that neutral and acidic human milk oligosaccharides can be absorbed and cross the border membrane of the intestine, which suggests that human milk oligosaccharides may act systemically and that their effect is not restricted to the intestine (28) . However, because serious infectious morbidity was the primary aim of our study, future studies including a larger number of preterm infants are needed to confirm the effect of SC GOS/ LC FOS/AOS on BPD.
In our study, the incidence of necrotizing enterocolitis was not different between groups. Approximately 50% of the infants who developed necrotizing enterocolitis did not reach a mean supplementation dose of !50% during the study period or died before the end of the study period. Therefore, we cannot draw conclusions about the effect of SC GOS/ LC FOS/AOS supplementation on the incidence of necrotizing enterocolitis.
Some limitations of the study need to be addressed. First, the analysis of CoNS-and non-CoNS (= endogenous) infections was a post hoc analysis based on the assumption that CoNS infections are most commonly related to (the combination of) indwelling lines and parenteral feeding and not to the microbiota of the gastrointestinal tract. As a consequence, the sample size was not sufficient to detect significant differences in the intention-to-treat analysis. Second, randomization was primarily based on birth weight, whereas gestational age was also an inclusion criterion. As a consequence, there was a nonsignificant difference in gestational age between both groups in favor of the SC GOS/ LC FOS/ AOS group. However, adjustment for gestational age and other potential confounders defined in our study protocol did not change the results of our primary outcome. Third, study supplementation started 48 h after birth, because parents were allowed 48 h to give informed consent. Fourth, an optimal supplementation dose of 1.5 g Á kg 21 Á d 21 was reached at a median postnatal age of 11 d because of restriction of the maximal osmolarity of the enteral feeding, consistent with a maximum oligosaccharides supplementation of 1 g/60 mL feeding. Last, breast milk itself contains neutral and acidic oligosaccharides, and the effect of supplementation on infectious morbidity may be less pronounced in preterm infants who were exclusively breastfed. However, in an additional analysis, to determine the influence of type of feeding on infectious morbidity, we did not find that exclusive breastfeeding during the study period reduced the incidence of serious infections. Because breast milk is strongly promoted in our NICU, most infants received breast milk (.60%), and relatively few were exclusively formula fed (20%).
Serious infections morbidity is the most common cause of death during the neonatal period and is a major risk of neurologic impairment. The potential improvement in short-and long-term outcomes with supplementation of health-promoting nutrients is very attractive. Human milk contains, besides oligosaccharides, other beneficial nutrients such as glycoproteins. Recently, Mazoni et al (29) found that supplementation of bovine lactoferrin with or without the probiotic strain Lactobacillus rhamnosus GG reduced the risk of late-onset sepsis in very-low-birth-weight infants. In a recent review of the potential roles and clinical utility of prebiotics in newborns, Sherman et al (30) concluded that when taken in sufficient amounts, prebiotics soften stools, increase stool frequency, and increase the ratio of bifidobacteria to total fecal bacteria. Furthermore, Sherman et al concluded that the addition of a prebiotic mixture to formula is considered safe. However, additional research is needed to determine the relevance of reported outcome measures for decreasing disease and promoting health.
In summary, we found that enteral supplementation of SC GOS/ LC FOS/AOS does not significantly reduce the risk of serious infectious morbidity in preterm infants. However, there was a trend toward a lower incidence of serious infectious morbidity, especially for infections with endogenous bacteria. This finding suggests a possible beneficial effect that should be evaluated in a larger study. Because serious infectious morbidity during the neonatal period is associated with neurodevelopmental impairment (31, 32) , decreasing the risk of serious infectious morbidity by nutritional supplementation, such as with prebiotics, should be investigated further.
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